NCT03589339
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Other, Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have a diagnosis that is indicated to receive anti-PD-1 therapy
Exclusions: Patients who have received more than one prior line of immunotherapy; Patients with symptomatic central nervous system metastases and/or carcinomatous meningitis
https://ClinicalTrials.gov/show/NCT03589339